Angiotensin-converting enzyme genotype is a predictive factor in the peak panel-reactive antibody response

Transplantation Proceedings

Volumn 36, Issue 1, 2004, Pages 35-37

  Akcay A ^a   Ozdemir F N ^a,b   Atac F B ^a   Sezer, S ^a   Verdi, H ^a   Arat, Z ^a   Haberal, M ^a  

^a BASKENT UNIVERSITY   (Turkey)

^b Baskent Universitesi Ankara Hastanesi   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; DIPEPTIDYL CARBOXYPEPTIDASE; HLA ANTIBODY;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SCREENING; BLOOD TRANSFUSION; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR;

EID: 0842281695     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2003.11.013     Document Type: Conference Paper

References (13)

1. Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol Dial Transplant. 16:2001;897.
2. Cecka JM. The UNOS Scientific Renal Transplant Registry. Clin Transpl 1, 1998.
3. Fellstrom B. Nonimmune risk factors for chronic renal allograft dysfunction. Transplantation. 71:(Suppl):2001;10.
4. Wolf G., Neilson E.G. Angiotensin II as a renal growth factor. J Am Soc Nephrol. 3:1993;1531.
5. Lalouel J.M., Rohrwasser A., Terreros D., et al. Angiotensinogen in essential hypertension from genetics to nephrology . J Am Soc Nephrol. 12:2001;606.
6. Hollenberg N.K. Renal implications of angiotensin receptor blockers. Am J Hypertens. 14:2001;237.
7. Abdi R., Huong T.T.B., Zee R., et al. Angiotensin gene polymorphism as a determinant of posttransplantation renal dysfunction and hypertension. Transplantation. 72:2001;726.
8. Nicod J., Richard A., Frey F.J., et al. Recipient RAS gene variants and renal allograft function. Transplantation. 73:2002;960.
9. Haznedaroglu I.C., Ozturk M.A. Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol. 35:2003;867.
10. Rodgers K.E., Xiong S., Steer R., et al. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 18:2000;287.
11. Gaston R.S., Julian B.A., Curtis J.J. Posttransplant erythrosis an enigma revisited . Am J Kidney Dis. 24:1994;277.
12. Inigo P., Torregrosa J.V., Campistol J.M., et al. Treatment with losartan in kidney transplant recipients with posttransplant erythrocytosis. Transplant Proc. 31:1999;2321.
13. Macdougall I.C. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant. 14:1999;1836.